Interleukin Genetics Inc (ILIU)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Interleukin Genetics Inc (ILIU) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012210
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:32
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Interleukin Genetics Inc (Interleukin) is a molecular diagnostics company which develops and distributes genetic tests for the personalized health market. Its major genetic tests include ILUSTRA genetic risk test ; cardiovascular risk test; weight management genetic test; bone health genetic test; heart health genetic test; nutritional needs genetic test; and wellness select genetic test. ILUSTRA genetic test analyzes genetic variations associated with inflammation and helps in identifying individuals who are at increased risk for severe periodontal disease. The company distributes its products through partnership with healthcare professionals, health and wellness companies, and distribution channels. Interleukin is headquartered in Waltham, Massachusetts, the US.

Interleukin Genetics Inc (ILIU) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Interleukin Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Interleukin Genetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Interleukin Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Interleukin Genetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Interleukin Genetics Inc, Medical Devices Deals, 2011 to YTD 2017 9
Interleukin Genetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Interleukin Genetics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Interleukin Genetics Enters Into Research Collaboration With Metagenics 11
Equity Offering 12
Interleukin Genetics Raises USD5.6 Million in Private Placement of Shares 12
Debt Offering 14
Interleukin Genetics Raises USD1 million in Issue of Subordinated Convertible Promissory Notes 14
Interleukin Genetics Inc – Key Competitors 15
Interleukin Genetics Inc – Key Employees 16
Interleukin Genetics Inc – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Financial Announcements 18
May 12, 2017: Interleukin Genetics Reports First Quarter 2017 Financial Results 18
Apr 18, 2017: Interleukin Genetics Reports Fourth Quarter and Year-End 2016 Financial Results 20
Nov 15, 2016: Interleukin Genetics Reports Third Quarter 2016 Financial Results 22
Aug 16, 2016: Interleukin Genetics Reports Second Quarter 2016 Financial Results 24
May 16, 2016: Interleukin Genetics Reports First Quarter 2016 Financial Results 26
Mar 17, 2016: Interleukin Genetics Reports Fourth Quarter and Year-End 2015 Financial Results 28
Corporate Communications 30
Jul 03, 2017: Interleukin Genetics To Explore Strategic Alternatives, Reduce Workforce 30
Other Significant Developments 31
Feb 15, 2017: IG and PBGH Forge Relationship To Bring ILUSTRATM To Pittsburgh Employers 31
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32

List of Tables
Interleukin Genetics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Interleukin Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Interleukin Genetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Interleukin Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Interleukin Genetics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Interleukin Genetics Inc, Medical Devices Deals, 2011 to YTD 2017 9
Interleukin Genetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Interleukin Genetics Enters Into Research Collaboration With Metagenics 11
Interleukin Genetics Raises USD5.6 Million in Private Placement of Shares 12
Interleukin Genetics Raises USD1 million in Issue of Subordinated Convertible Promissory Notes 14
Interleukin Genetics Inc, Key Competitors 15
Interleukin Genetics Inc, Key Employees 16

★海外企業調査レポート[Interleukin Genetics Inc (ILIU)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • BE Semiconductor Industries NV (BESI):企業の財務・戦略的SWOT分析
    BE Semiconductor Industries NV (BESI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • CoLucid Pharmaceuticals Inc (CLCD)-製薬・医療分野:企業M&A・提携分析
    Summary CoLucid Pharmaceuticals Inc (CoLucid) is a pharmaceutical company that conducts research and develops new therapies. CoLucid’s lead product candidate Lasmiditan (COL-144), is an oral tablet that penetrates the central nervous system and selectively targets 5-HT1F receptors expressed in the t …
  • Birks Group Inc (BGI):企業の財務・戦略的SWOT分析
    Birks Group Inc (BGI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Qvella Corp:医療機器:M&Aディール及び事業提携情報
    Summary Qvella Corp (Qvella) is a molecular diagnostics company which develops differentiated technology for rapid detection of pathogens causing Sepsis by direct sampling of bodily fluids. Its Field Activated Sample Treatment (FAST) -ID technology utilizes a novel electrical lysing and sample treat …
  • Seylan Bank Plc
    Seylan Bank Plc - Strategy, SWOT and Corporate Finance Report Summary Seylan Bank Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Open Monoclonal Technology Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Open Monoclonal Technology Inc (OMT), a subsidiary of Ligand Pharmaceuticals Inc, is a biotechnology company that discovers and develops human monoclonal antibody platform based on transgenic rats. The company provides products such as omnirat, omnimouse and omniflic. Its omnirat is an antib …
  • Armed Forces Insurance:企業の戦略的SWOT分析
    Armed Forces Insurance - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Cardiac Science Corp:企業の戦略的SWOT分析
    Cardiac Science Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • SeraCare Life Sciences Inc:企業の戦略的SWOT分析
    SeraCare Life Sciences Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Great Basin Scientific Inc (GBSN)-医療機器分野:企業M&A・提携分析
    Summary Great Basin Scientific Inc (Great Basin) is a molecular diagnostics company that offers technology products. The company develops and distributes point-of-care technology and products to improve automation, throughput, scalability, reliability and ease-of-use in rapid diagnostic testing. It …
  • Hoteli Maestral d.d.:企業の戦略・SWOT・財務情報
    Hoteli Maestral d.d. - Strategy, SWOT and Corporate Finance Report Summary Hoteli Maestral d.d. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Breg Inc:医療機器:M&Aディール及び事業提携情報
    Summary Breg Inc (Breg) is a medical device company that manufactures and distributes sports medicine and rehabilitation products. The company offers products such as knee braces, cold therapy, dvt prophylaxis, hip bracing, shoulder bracing, fracture bracing, elbow wrist bracing, spine bracing, foot …
  • Helix BioPharma Corp (HBP)-製薬・医療分野:企業M&A・提携分析
    Summary Helix BioPharma Corp (Helix) is a biopharmaceutical company with a focus in the field of cancer therapy. The company develops drug candidates for the prevention and treatment of cancer. It develops drugs based on its proprietary technologies. DOS47, the company's proprietary broad anti-cance …
  • Sega Sammy Holdings Inc (6460):企業の財務・戦略的SWOT分析
    Sega Sammy Holdings Inc (6460) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • China Petroleum & Chemical Corp (600028):電力:M&Aディール及び事業提携情報
    Summary China Petroleum & Chemical Corp (Sinopec Corp), a subsidiary of China Petrochemical Corporation, is a vertically integrated energy and chemical company. It is involved in the oil and gas exploration and production, extraction, pipeline transmission and marketing; oil refining; and production …
  • Sanofi India Ltd (SANOFI):企業の財務・戦略的SWOT分析
    Summary Sanofi India Ltd (Sanofi India), formerly Aventis Pharma Ltd, a subsidiary of Sanofi is a healthcare company that manufactures and markets pharmaceutical and prescription products. The company offers products in the form of capsules, tablets, insulin, injection, creams and gels, and solution …
  • TransMontaigne Partners LP (TLP):企業の財務・戦略的SWOT分析
    Summary TransMontaigne Partners LP (TLP), a subsidiary of TransMontaigne GP LLC is an energy infrastructure service provider that offers integrated terminaling, transportation, and storage services. The company distributes and transports crude oil, chemicals, petroleum products, fertilizers, and oth …
  • Sygnis AG (LIO1):医療機器:M&Aディール及び事業提携情報
    Summary Sygnis AG (Sygnis), formerly Sygnis Pharma AG is a developer of novel products and tools in the field of molecular biology. The company undertakes development and marketing of new molecular biological technologies for DNA amplification and sequencing. Its offers products such as single cell …
  • Besins Healthcare SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Besins Healthcare SA (Besins) is a pharmaceutical company that develops drugs for the well-being of men and women. The company offers AndroGel, a topical testosterone gel for hypogonadism. It also provides Oestrogel, a transdermal estradiol gel. Besins’ women's health products are used for t …
  • TTEC Holdings Inc.:企業の戦略・SWOT・財務情報
    TTEC Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary TTEC Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆